



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 652 934 A1**

(12) **EUROPEAN PATENT APPLICATION**
published in accordance with Art. 158(3) EPC

(43) Date of publication:
03.05.2006 Bulletin 2006/18

(21) Application number: **04771221.1**

(22) Date of filing: **27.07.2004**

(51) Int Cl.:
C12Q 1/48 ^(1980.01) **C12N 9/12** ^(1980.01)
G01N 33/50 ^(1980.01) **C07K 19/00** ^(1995.01)
C12N 15/00 ^(1980.01)

(86) International application number:
PCT/JP2004/011186

(87) International publication number:
WO 2005/010208 (03.02.2005 Gazette 2005/05)

(84) Designated Contracting States:
DE FR GB

(30) Priority: **29.07.2003 JP 2003202992**

(71) Applicant: **Japan Science and Technology Agency**
Kawaguchi-shi,
Saitama 332-0012 (JP)

(72) Inventor: **KURODA, Akio**
Higashihiroshima-shi,
Hiroshima 7390026 (JP)

(74) Representative: **MacLean, Martin Robert**
Mathys & Squire
120 Holborn
London EC1N 2SQ (GB)

(54) **IMPROVED METHOD OF AMPLIFYING ATP AND USE THEREOF**

(57) The ATP amplification method of the present invention is a method for amplifying and detecting a very trace amount of exogenous ATP by allowing a fusion protein (PPK-ADK) of a polyphosphate kinase and an adenylate kinase, the fusion protein not containing ADP, to act on a mixture of ATP, AMP, and a polyphosphate

compound. The present invention also provides an ultrasensitive ATP amplification method by which ATP at a single cell level can be amplified and detected, and an ultrasensitive microbial assay based on this ATP amplification method.

EP 1 652 934 A1

Description

Technical Field

5 **[0001]** The present invention relates to a method for amplifying ATP, a method for rapidly detecting the presence of a microorganism using the amplification method, and a kit for the detection method.

Background Art

10 **[0002]** In the food industry, dairy industry, and other industries, methods for rapidly detecting microorganisms with high sensitivity are very important, for example, in the control of environmental microorganisms such as the detection of microorganisms at food manufacturing plants for prevention of food poisoning, and in the inspection for contamination of microorganisms in food products (e.g., dairy products such as milk). In conventional methods for detecting living cells using a nutrient medium, it takes several days until a living microorganism is counted.

15 **[0003]** For the detection of microorganisms as described above, a method of utilizing ATP present in all organisms has been examined. As a method for detecting ATP, a bioluminescence assay employing firefly luciferase has been known. This method is an established technique for measuring ATP (see DeLuca, M. and W. D. McElroy, "Kinetics of the firefly luciferase catalyzed reactions," *Biochemistry*, vol. 26, pp. 921-925 (1974)) and has been used as a rapid, hygiene monitoring (Bautista, D. A. et al., "Adenosine triphosphate bioluminescence as a method to determine microbial levels in scald and chill tanks at a poultry abattoir," *Poult. Sci.*, vol. 73, pp. 1673-1678 (1994)). Furthermore, an ATP assay has recently been proposed as a technology for countering bioterrorism (Spencer, R. C. and N. F. Lightfoot, "Preparedness and response to bioterrorism," *J. Infect.*, vol. 48, pp. 104-110 (2001)).

20 **[0004]** However, the conventional methods for assaying ATP have a detection limit (e.g., approximately 10^4 E. coli colony-forming units (CFU)/assay). Such a sensitivity is not sensitive enough for industrial or practical applications.

25 **[0005]** A computer simulation has suggested that ATP amplification employing adenylate kinase (ADK) and pyruvate kinase (PVK) provides a possibility that a very low level of ATP can be detected without using a photometer having high sensitivity (Chittock, R. S. et al., "Kinetic aspects of ATP amplification reactions," *Anal. Biochem.*, vol. 255, pp. 120-128 (1998)). However, this method has not been utilized in practice.

30 **[0006]** In order to assay a trace amount of ATP, a method for amplifying ATP has been proposed (Japanese Laid-Open Patent Publication No. 2001-299390). This method disclosed in Japanese Laid-Open Patent Publication No. 2001-299390 will be described with reference to Fig. 1. In Fig. 1, ADK refers to adenylate kinase, polyP refers to polyphosphate, and PPK refers to polyphosphate kinase. Hereinafter, these abbreviations sometimes are also used in the present specification, Fig. 1a shows that in the absence of ATP, ATP is not theoretically produced from AMP and polyphosphate. As shown in Fig. 1b, in the presence of ATP, ADK causes a transphosphorylation from ATP to AMP, which results in a production of two molecules of ADP (first reaction). The two molecules of ADP produced in this first reaction receive a phosphate group from polyphosphate by the action of PPK, resulting in a production of two molecules of ATP (second reaction). The two molecules of ATP produced in this second reaction are used again for the first reaction to produce four molecules of ADP, and these four molecules of ADP are then converted into four molecules of ATP by PPK.

35 **[0007]** In this manner, according to Japanese Laid-Open Patent Publication No. 2001-299890, excess amounts of AMP and polyphosphate are added to the reaction system to drive the ADK and PPK equilibrium toward the production of ADP (first reaction) and the production of ATP (second reaction), respectively. Then, by repeating a single reaction system including the first reaction and the second reaction n times, one molecule of ATP is amplified to 2^n molecules of ATP. Therefore, this method is an excellent method for amplifying ATP.

40 **[0008]** Although this method described in Japanese Laid-Open Patent Publication No. 2001-299390 is an excellent method in that the presence of cells can be detected with a higher level of sensitivity than conventionally achieved, it turned out that in this method, amplification of ATP in the absence of ATP, which does not occur in theory, is sometimes observed at a low level, and thus there is a problem in that this method does not have reliability for amplifying and detecting exogenous (externally added) ATP only. That is to say, there is a problem in that this method cannot reliably provide such a sensitivity that ATP at a single cell level can be amplified and detected. Furthermore, there are also problems such as the adjustment between the activities of ADK and PPK.

Disclosure of Invention

45 **[0009]** There is a demand for a method for efficiently amplifying exogenous ATP. In particular, there is a demand for a method for amplifying exogenous ATP only and a high-sensitive detection method by which the presence of a single cell can be detected using this amplification method.

50 **[0010]** The present invention was achieved in order to solve the foregoing problems. By the ATP amplification method of the present invention, a very trace amount of ATP can be detected, and furthermore, the presence of only a single

cell can be detected.

[0011] The present invention provides a method for amplifying ATP, including allowing a fusion protein of a polyphosphate kinase and an adenylate kinase to act on a mixture containing ATP, AMP, and a polyphosphate compound,

[0012] In a preferred embodiment, the fusion protein of a polyphosphate kinase and an adenylate kinase is a fusion protein that does not contain ADP.

[0013] Moreover, the present invention provides a method for detecting ATP, including allowing a fusion protein of a polyphosphate kinase and an adenylate kinase to act on a mixture of ATP, AMP, and a polyphosphate compound to amplify ATP; and detecting the amplified ATP.

[0014] In a preferred embodiment, the fusion protein of a polyphosphate kinase and an adenylate kinase is a fusion protein that does not contain ADP.

[0015] Furthermore, the present invention provides a method for rapidly detecting the presence of a microorganism, including treating a sample containing a microorganism to prepare a sample containing ATP; adding the sample containing ATP to an ATP amplification system to amplify ATP; and detecting the amplified ATP, wherein the ATP amplification system includes AMP, a polyphosphate compound, and a fusion protein of a polyphosphate kinase and an adenylate kinase, the fusion protein not containing ADP.

[0016] Moreover, the present invention provides a kit for rapidly detecting the presence of a microorganism, including an ATP amplification reagent containing AMP, a polyphosphate compound, and a fusion protein of a polyphosphate kinase and an adenylate kinase, the fusion protein not containing ADP; and an ATP detection reagent for detecting ATP

[0017] In a preferred embodiment, the kit further includes a cell lysis reagent.

[0018] The present invention further provides a method for amplifying ATP by allowing an adenylate kinase and a polyphosphate kinase that does not contain ADP to act on a mixture of ATP, AMP, and a polyphosphate compound.

[0019] The present invention also provides a fusion protein of a polyphosphate kinase and an adenylate kinase, and a fusion protein of a polyphosphate kinase and an adenylate kinase, which does not contain ADP.

Brief Description of Drawings

[0020]

Fig. 1 is a schematic diagram showing an ATP amplification mechanism employing ADK and PPK.

Fig. 2 is a graph showing the results of ATP amplifications employing a PPK-ADK and an apyrase-treated PPK-ADK.

Fig. 3 is a graph showing the results of ATP amplifications performed on samples containing very trace amounts of ATP.

Fig. 4 is a graph showing the results of ATP amplifications performed on samples containing cells in predetermined concentrations,

Best Mode for Carrying Out the Invention

(Fusion protein)

[0021] Regarding the fusion protein of a polyphosphate kinase and an adenylate kinase (hereinafter sometimes referred to as the "PPK-ADK") that is used in the present invention, the order of a linkage of the enzymes is not particularly limited as long as the fusion protein reveals the PPK activity and ADK activity. The fusion protein preferably contains the PPK on the N-terminal side and the ADK on the C-terminal side. In this fusion protein, the PPK may be bound to the ADK directly or via a spacer. To purify the fusion protein, it is useful to attach a tag that does not affect the expression of the enzymes to the C-terminal of the fusion protein.

[0022] There is no particular limitation regarding the sources of a ppk gene encoding the PPK and an adk gene encoding the ADK, as long as the sequences of these genes are identified. The sequences of *E. coli* are preferably used.

[0023] By preparing appropriate primers based on these gene sequences and performing PCR, respective gene sequences can be obtained.

[0024] As a suitable primer for preparing the ppk gene, for example, a combination of the following primers is preferable: (1) a primer having a sequence for introducing an appropriate restriction enzyme recognition site upstream of the 5' end of the ppk gene; and (2) a primer having a spacer (e.g., glycine) sequence and a sequence for introducing an appropriate restriction enzyme recognition site in the spacer site or downstream thereof. When PCR is performed by using a combination of these two primers, a fragment containing a ppk gene that expresses a PPK having a spacer at the C-terminal is collected easily.

[0025] As a suitable primer for preparing the adk gene, the following primers are preferable as in the case of the ppk gene: (1) a primer having a sequence for introducing an appropriate restriction enzyme recognition sequence upstream of the 5' end of the adk gene; and (2) a primer having a C-terminal tag (e.g., histidine) sequence and having a sequence

for introducing an appropriate restriction enzyme recognition sequence downstream of the C-terminal tag. When PCR is performed using a combination of these two primers, a fragment containing an *adk* gene that expresses an ADK having a tag at the C-terminal is collected easily.

[0026] Restriction enzymes of the above-described primers can be determined in view of the gene sequence of *ppk* or *adk* and a cloning site of a vector into which fragments are to be incorporated.

[0027] PCR is performed using the chromosomal DNA of *E. coli* as a template and the above-described primers, and the obtained DNA fragments are each cleaved with restriction enzymes to collect a fragment containing the *ppk* gene and a fragment containing the *adk* gene. The obtained fragments containing the respective genes are inserted into an appropriate vector so as to be arranged in order of *ppk*-*adk*, and thus a recombination vector that expresses a fusion protein of PPK-ADK can be obtained.

[0028] The obtained vector is introduced into an appropriate host (e.g., *E. coli*) to express the recombinant vector, and thus the PPK-ADK fusion protein is produced. The fusion protein designed to have a histidine tag (His-tag) is purified and collected easily by using a Hitrap chelating column.

[0029] The obtained fusion protein, PPK-ADK, can be used for an ATP amplification without being subjected to any treatment. However, as discussed below, it turned out to be improper to measure exogenous ATP. This may be because ADP is present as bound to PPK. The ADP bound to PPK may serve as a substrate of the PPK in the presence of a polyphosphate compound, and this ADP may be converted into ATP by PPK. That is to say, it seems that in a reaction system as shown in Fig. 1, a reaction from ADP to ATP, which is the second reaction, occurs first even in the absence of ATP, and this ATP is then used in the first reaction, thereby initiating an ATP amplification automatically. Therefore, in order to measure exogenous ATP only, it is necessary to remove the ADP bound to the PPK in advance.

[0030] Removal of the ADP, which is an impurity bound to PPK, is performed by an apyrase treatment, for example. Apyrase removes a phosphate group from ATP or ADP to produce AMP. The apyrase treatment is preferably performed in the presence of an appropriate amount of pyrophosphate. Pyrophosphate promotes release of the ADP bound to PPK-ADK, so that the ADP becomes susceptible to attack by apyrase. The apyrase-treated PPK-ADK is collected using a Hitrap chelating column again. The collected PPK-ADK retains the respective activities (i.e., PPK activity and ADK activity) even after the apyrase treatment.

(Amplification of ATP using PPK-ADK)

[0031] The amplification of ATP using the PPK-ADK of the present invention is performed by allowing the PPK-ADK to act on ATP, an excess amount of AMP, and an excess amount of a polyphosphate compound. That is to say, it is performed by adding ATP to a mixture of AMP, the polyphosphate compound, and the PPK-ADK or by adding the PPK-ADK to a mixture of ATP, AMP, and the polyphosphate compound. The mode of the reaction is the same as in Fig. 1, and the first reaction and the second reaction shown in Fig. 1 are repeated to amplify ATP.

[0032] The amplification of ATP is performed in an appropriate buffer solution at an appropriate temperature (e.g., 30 to 40°C) for an appropriate period of time (e.g., 5 minutes to 2 hours). When it seems that ATP is present in a trace amount, the amplification reaction is preferably performed for about one hour.

[0033] As the polyphosphate compound, polyphosphoric acid or a salt thereof is used. Preferably, a compound in which 10 to 1000, preferably 10 to 100 phosphate molecules are linearly polymerized is used advantageously. The polyphosphate may be derived from bacteria or may be chemically synthesized. Alternatively, it may be synthesized from ATP using a polyphosphate synthetase.

(Detection of ATP)

[0034] Regarding the method for detecting the amplified ATP, a method usually used by those skilled in the art can be employed, and there is no particular limitation. Generally, the detection is performed by measuring the amount of luminescence due to a reaction of a luciferase with ATP. For example, a commercially available ATP measurement kit employing luciferase can be used.

(Method for rapidly detecting the presence of a microorganism)

[0035] This method is a method in which, focusing on the fact that ATP is contained in the cells of all organisms, a sample containing ATP is prepared from a sample containing a microorganism, and ATP is amplified using the above-described ATP amplification method and detected. The use of the PPK-ADK subjected to the ADP removal treatment allows the measurement of exogenous ATP. For example, ATP contained in a single cell can be amplified to a measurable level, so that the presence of only one microorganism can be detected. Considering that the detection limit of the conventional methods was 10^4 colony-forming units (CFU) of *E. coli* per assay, the detection sensitivity is increased by a factor of at least 10,000.

5 [0036] It should be noted that the microorganism contains ADP. When the PPK-ADK subjected to the ADP removal treatment is used, when ADP is added to the amplification system of the present invention, the ADP is converted into ATP, and thus an ATP amplification is initiated. Therefore, the amplification method of the present invention is superior in that even when ATP is degraded into ADP during a pre-treatment for the detection of a microorganism, the sensitivity in the present invention is not affected. Hereinafter, in the context of the detection of a microorganism, a sample of ATP to be measured is meant to include a case where ADP is contained in the sample.

10 [0037] There is no particular limitation regarding the method for preparing an ATP-containing sample from a microorganism-containing sample. It is possible to lyse a cell, but in view of influences of enzymes such as PPK and ADK contained in that cell, a method of performing a heat treatment to elute ATP or a method of lysing the cell, eluting ATP, and then performing a heat treatment for inactivating the other enzymes is most preferably employed. The heat treatment is performed, for example, at 100°C for 1 to 5 minutes. The cell lysis treatment can be performed using a lysis buffer, e.g., a lysis buffer that is included with a commercially available ATP assay kit.

15 [0038] Such a sample that is obtained by performing the ATP release treatment and that seems to contain ATP is added to a mixture of AMP, the polyphosphate compound, and the PPK-ADK to perform an ATP amplification, and then the presence of ATP is detected using, for example, an ATP detection method employing luciferase. If ATP is contained in the sample, then it reacts with the luciferase and luminescence is observed. It should be noted that since ATP is amplified, a luminometer having high sensitivity is not necessarily required.

20 [0039] The present invention also provides a kit for rapidly detecting the presence of such a microorganism. That is to say, a kit including an ATP amplification reagent containing AMP, polyphosphate, and a PPK-ADK that does not contain ADP and an ATP detection reagent for detecting ATP is provided. This kit may further include a cell lysis reagent. The composition of the cell lysis reagent may be changed depending on the cells to be detected (e.g., a microorganism, a somatic cell, and the like).

25 [0040] The presence of a microorganism can be detected rapidly by subjecting a sample that seems to contain the microorganism to a heat treatment, adding the sample to the ATP amplification reagent of this kit to perform an amplification for an appropriate period of time, and then confirming the presence of ATP with the ATP detection reagent. This method was accomplished by use of PPK-ADK obtained by performing the ADP removal treatment so as to detect exogenous ATP. As the ATP detection reagent, a reagent using a luciferase-luciferin reaction system is commonly used, and the term "ATP detection reagent" used herein conceptually includes also a bioluminescence (fluorescence) measuring instrument.

30 (ATP amplification using ADK and PPK that does not contain ADP)

35 [0041] The present invention also provides a method for amplifying ATP by allowing an ADK and a PPK that does not contain ADP to act on a mixture containing ATP, AMP, and polyphosphate. The PPK that does not contain ADP is prepared, for example, in the same manner as in the preparation of the fusion protein described above. In brief, a DNA fragment containing a ppk gene that expresses a PPK having a His-tag is collected using a primer having an appropriate restriction enzyme recognition sequence upstream of the 5' end of the ppk gene and a primer having a His-tag sequence and having an appropriate restriction enzyme recognition sequence downstream thereof. The obtained DNA is introduced into an appropriate vector to obtain a recombinant plasmid, which is then introduced into E. coli to express the PPK. The PPK is purified by using a Hitrap chelating column, treated with apyrase in the presence of pyrophosphate, and subjected to a Hitrap chelating column again to collect the PPK from which ADP has been removed. By using this PPK in the reaction system shown in Fig. 1, a method for amplifying and detecting exogenous ATP only is provided.

45 Examples

[0042] Hereinafter, the present invention will be described by means of examples, but the present invention is not limited to these examples.

50 [0043] In the examples, AMP and ATP used were purchased from Wako Pure Chemical Industries, Ltd. (Osaka) and Sigma, respectively. The AMP was further purified by using a TSKgel SAX column (TOSOH) with 0.2 M KCl and 1% EDTA (pH 10) as a solvent. As the polyphosphate, polyphosphate having an average chain-length of 65 (Sigma) was used. A bioluminescence assay kit (CLSII) including luciferin and luciferase was purchased from Roche. Apyrase was purchased from Sigma.

(Example 1: Preparation of PPK-ADK)

55 [0044] Primers for obtaining a gene (ppk) encoding E. coli polyphosphate kinase (see Akiyama, M, et al., "The polyphosphate kinase gene of Escherichia coli. Isolation and sequence of the ppk gene and membrane location of the protein," J. Biol. Chem., vol. 267, pp. 22556.22581 (1992)) are as follows:

GGATCTAGATGAATAAAACGGAGTAAAAGT (SEQ ID No: 1)

and

GGAGGATCCGCCGCCGCCCTTCAGGTTGTTTCGAGTGATTT

(SEQ ID No: 2).

[0045] The primer of SEQ ID No: 1 has a sequence for introducing a restriction enzyme XbaI recognition site in the 5' terminal of the ppk gene. SEQ ID No: 2 is designed so that four glycines are attached to the C-terminal of the PPK, and further has a sequence for introducing a restriction enzyme BamHI recognition site in the 3' terminal.

[0046] Primers for obtaining a gene (adk) encoding E. coli adenylate kinase gene (Brune, M. et al., "Cloning and sequencing of the adenylate kinase gene (adk) of Escherichia coli," Nucleic Acids Res., vol. 13, pp. 7139-7161 (1985)) are as follows:

GGAGGATCCATGCGTATCATTCTGCTTGGC (SEQ ID No: 3)

and

GGAAAGCTTGCCGAGGATTTTTTCCAG (SEQ ID No: 4).

[0047] The primer of SEQ ID No: 3 has a sequence for introducing a restriction enzyme BamHI recognition site in the 5' terminal of the adk gene. The primer of SEQ ID No: 4 is designed so that histidine, which is a C-terminal tag, is attached to the C-terminal of the ADK, and further has a sequence for introducing a restriction enzyme HindIII recognition site in the 3' terminal.

[0048] PCR was performed in the commonly used manner by using the chromosomal DNA of E. coli as a template and the above-described primers to obtain DNA fragments containing the ppk gene and the adk gene, respectively. The obtained DNA fragment containing the ppk gene was inserted into a pGEMT vector (Promega) to obtain a pGEMTppk. The obtained DNA fragment containing the adk gene was inserted into a pGEMT vector (Promega) to obtain a pGEMTadk.

[0049] A 2.1 kb fragment obtained by digesting the pGEMTppk with XbaI-BamHI and a 0.6 kb fragment obtained by digesting the pGEMTadk with BamHI-HindIII were ligated to a XbaI-HindIII digest of a pET vector (Stratagene), thereby constructing a plasmid pETppkadk. This plasmid contains a gene encoding a fusion protein of PPK and ADK with C-terminal His-tag in which PPK is bound to ADK via the four glycines.

[0050] This plasmid pETppkadk was introduced into E. coli (E. coli BL21), and the resultant transformant was cultured for 2 hours, and then 1 mM IPTG was added to a growth medium. After 4 hours of incubation, the transformant was harvested by centrifugation and suspended in a 20 mM phosphate buffer (pH 7) containing 0.5 M NaCl. The cells were lysed with a B-PER reagent (Pierce) and then treated with DNase and RNase in the presence of 1 mM PMSF. The supernatant was obtained by centrifugation, filtrated through a 0.2 μm filter, and then loaded onto a Hitrap chelating column (Amersham Bioscience). The column was washed with 0.1 M pyrophosphate, 20 mM phosphate, 0.5 M NaCl, 50 mM imidazole, and 20% glycerol (pH 7.4). A PPK-ADK fusion protein was eluted with 0.1 M pyrophosphate, 20 mM phosphate, 0.5 M NaCl, 0.5 M imidazole, and 20% glycerol (pH 7.4).

[0051] The obtained PPK-ADK fusion protein had the activities of ADK (43 U/mg) and PPK (88 U/mg) and produced ATP from AMP and polyphosphate. It should be noted that one unit of PPK synthesizes 1.0 μmol/minute of ATP from ADP and polyphosphate at 37°C. One unit of ADK synthesizes 1.0 μmol/minute of ATP from ADP at 37°C.

[0052] Then, 50 μl of a reaction mixture containing 0.16 μg of the PPK-ADK, 10 μM AMP, 400 μM polyphosphate, 8 mM MgCl₂, and 60 mM Tris-HCl (pH 7.4) were prepared. Then, 5 μl of the reaction mixture were sampled and mixed with 40 μl of the ATP bioluminescence assay reagent (Roche), and luminescence was measured immediately by using a multiplate luminometer (ARVO, Wallac).

[0053] As indicated by PPK-ADK in Fig. 2, amplification of ATP occurred in this reaction system that did not contain ATP, and luminescence was observed. The cause of this phenomenon was examined, and it was suggested that since ADP was bound to the PPK, this ADP was used by the PPK to firstly cause the second reaction shown in Fig. 1 to produce ATP and this ATP might then be amplified.

EP 1 652 934 A1

(Example 2: Removal of ADP bound to PPK-ADK)

[0054] In order to remove the ADP, which was an impurity bound to the PPK-ADK obtained in Example 1, 180 μg of the PPK-ADK were reacted with apyrase (200 U) for one hour in the presence of 60 mM Tris-HCl (pH 8), 8 mM MgCl_2 and 10 mM polyphosphate. After the reaction was finished, the PPK-ADK from which the ADP was removed was collected by using a Hitrap chelating column again. Hereinafter, this PPK-ADK is referred to as the "apyrase-treated PPK-ADK". It should be noted that one unit of apyrase releases 1 μmol of phosphate from ATP or ADP per minute at 80°C.

[0055] Next, 50 μl of a reaction mixture containing 0.16 μg of the apyrase-treated PPK-ADK, 10 μM AMP, 400 μM polyphosphate, 8 mM MgCl_2 , and 60 mM Tris-HCl (pH 7.4) were prepared. Then, 5 μl of the reaction mixture were sampled and mixed with 40 μl of an ATP bioluminescence assay reagent (Roche), and luminescence was measured immediately by using a multiplate luminometer (ARVO, Wallac).

[0056] As shown in Fig. 2, in the reaction using the apyrase-treated PPK-ADK, luminescence was not observed even after 60 minute reaction. It should be noted that although not shown in the drawing, when ATP was added to this mixture, luminescence was observed. From this fact, it was found that the apyrase treatment does not affect the ADK activity and the PPK activity of the PPK-ADK and that as a result of removing the impurity, ADP, by the apyrase treatment, ATP amplification did not occur when the endogenous ATP was not added into the reaction mixture. Accordingly, it is believed that the luminescence observed when ATP was added was caused purely by the exogenous ATP. Therefore, the apyrase-treated (ADP-free) PPK-ADK is very useful in assay of exogenous ATP.

[0057] It should be noted that, in the apyrase treatment, it is preferable to add pyrophosphate to a washing buffer and an elution buffer when the PPK-ADK is adsorbed on a Hitrap chelating column and eluted from the column. Since 0.1 M pyrophosphate has an effect of releasing ADP from the PPK-ADK, ADP can be removed more efficiently.

(Example 3: Ultrasensitive bioluminescence assay)

[0058] First, 48 μl of a reaction mixture containing 0.16 μg of the apyrase-treated PPK-ADK, 10 μM AMP, 400 μM polyphosphate, 8 mM MgCl_2 , and 60 mM Tris-HCl (pH 7.4) were prepared, and then 2 μl of an ATP sample were added to this reaction mixture to amplify ATP. Thereafter, 6 μl of the reaction mixture were sampled over time and mixed with 40 μl of an ATP bioluminescence assay reagent, and luminescence was measured immediately by using a multiplate luminometer. For comparison, a sample was prepared without amplifying ATP (without adding the PPK-ADK), and the luminescence thereof was measured. Each value of luminescence is the mean \pm standard deviation of three different measurements. The increase in luminescence over time is shown in Fig. 3, and the results of ATP amplification after 60 minutes are shown in Table 1.

Table 1

ATP (fmol)	Luminescence (rlu)	
	ATP amplification	
	Without	With
330	913 \pm 22	28,180 \pm 1606
33	113 \pm 14	18,793 \pm 241
3.3	50 \pm 6	8,767 \pm 443
0.33	52 \pm 9	4,455 \pm 36
0.033	53 \pm 12	2,734 \pm 233
0.0033	52 \pm 12	1,553 \pm 102
0	51 \pm 2	229 \pm 28

[0059] As shown in Fig. 3, it was found that when exogenous ATP was not present, the apyrase-treated PPK-ADK did not amplify ATP at all in spite of an amplification treatment for 60 minutes. Furthermore, as shown in Fig. 8 and Table 1, it was found that in spite of a low initial concentration of ATP, ATP can be amplified to such an extent that luminescence can be measured. The results show that this ATP amplification is applicable to an ultrasensitive bioluminescence assay. In other words, it was shown that by subjecting a sample containing ATP in a concentration of 0.0088 femtomoles (fmol: 10^{-15} mol = 3.3 attomoles: 10^{-18} mol) to an ATP amplification treatment for 60 minutes, ATP can be amplified to a detectable level. That is to say, it became possible to detect ATP at a concentration of several attomoles (amol: 10^{-18} mol). On the other hand, conventional bioluminescence requires several tens femtomoles (fmol: 10^{-15} mol) of ATP to

EP 1 652 934 A1

measure the luminescence thereof (Table 1). Thus, it is shown that by using the ATP amplification method of the present invention, the sensitivity of bioluminescence was increased by a factor of at least 10,000.

(Example 4: Application of ultrasensitive bioluminescence assay in detecting a single microorganism)

[0060] The *E. coli* culture (2×10^9 CFU/ml) was diluted to an appropriate concentration with pure water. The cell suspension (500 μ l) was added to 500 μ l of a lysis buffer (bioluminescence assay kit, Roche) and heated to 100°C for 2 minutes to release ATP from the cells. Thereafter, 2 μ l of the heated sample were subjected to an ATP amplification assay to measure bioluminescence.

[0061] For comparison, a sample was prepared without amplifying ATP (without adding the PPK-ADK), and the luminescence thereof was measured. Each value of luminescence is the mean \pm standard deviation of three different measurements. The increase in luminescence over time is shown in Fig. 4, and the results of ATP amplification after 60 minutes are shown in Table 2.

Table 2

E. coli cells per assay (CFU)	Luminescence (rlu)	
	ATP amplification	
	Without	With
100,000	1,126 \pm 255	39,722 \pm 1,596
10,000	296 \pm 34	33,903 \pm 2,244
1,000	52 \pm 4	16,901 \pm 1890
100	37 \pm 4	6,823 \pm 205
10	39 \pm 6	3,280 \pm 604
1	37 \pm 7	1,714 \pm 44
0	43 \pm 12	364 \pm 73

[0062] As shown in Table 2 and Fig. 4, the amount of luminescence was varied depending on the number of *E. coli* cells used in the assay (Fig. 4). As shown in Table 2, when compared to the case where ATP amplification was not performed, the luminescent development was significantly enhanced in the case where ATP amplification was performed. Without ATP amplification, the degree of luminescent development was very low even in the case of 10,000 CFU in Table 2, and several 10,000 CFUs of *E. coli* cells were required to attain a significant level of bioluminescence. On the other hand, when the ATP amplification technique of the present invention was used, a distinct luminescence was observed even at the lowest level of a single *E. coli* cell (the level corresponding to 1 CFU of *E. coli* cell). This shows that the sensitivity was higher than in the case where ATP amplification was not performed by a factor of 10,000 or more.

[0063] It has been reported that the intracellular ATP level of the *E. coli* cells is about 7 μ mol/g dry cells (Neuhard, J., and Y. Nygaard, "Purines and pyrixnidines," pp. 445-473, F. C. Neidhardt at al. ed., "Escherichia coli and Salmonella typhimurium: cellular and molecular biology," ASM press, Washington, D. C. (1987)). Since the dry weight of one *E. coli* cell is about 2.8×10^{-18} g (F. C. Neidhardt, "Chemical composition of Escherichia coli," pp. 3-6, F. C. Neidhardt et al. ed., "Escherichia coli and Salmonella typhimurium: cellular and molecular biology," ASM press, Washington, D. C. (1987)), *E. coli* contains about 2 attomoles of ATP per cell. This level of ATP is almost equal to that of the detection limit of this ultrasensitive bioluminescence assay.

(Example 5: Application of ultrasensitive bioluminescence assay to hygiene monitoring)

[0064] The inventor of the present invention has examined whether or not the method of the present invention is applicable to swab monitoring of *E. coli*. First, a cell suspension of *E. coli* was spread on a polystyrene petri dish, air-dried, and swabbed with a commercially available cotton swab. Since the commercially available cotton swab contains a significant amount of ATP, it was previously autoclaved at 121°C for 75 minutes to decompose ATP to AMP and phosphate. The sample swabbed from a surface area of 4 cm² was dipped into 400 μ l of a lysis buffer, and then heated at 100°C for 2 minutes. The heated sample (10 μ l) was added to an ATP amplification reaction solution (40 μ l), and an ATP amplification reaction was performed for 60 minutes. Then, 25 μ l of the reaction mixture were used for a bioluminescence assay. The results are shown in Table 3.

Table 3

Number of E coli cells (CFU)	Luminescence (rlu)	
	ATP amplification	
	Without	With
120,000	223	30,630
12,000	62	23,835
1,200	52	10,215
120	51	2,685
12	53	1,653
0	65	404

[0065] By this swab monitoring, a measurement at a level of about 12 CFU of E. coli/cm² was possible. It was found that the method of the present invention is applicable to swab monitoring of E. coli.

(Example 6: Detection of bacteria in drinking water)

[0066] The inventor of the present invention has examined whether or not the method of the present invention is effective in detecting bacteria in drinking water. First, a water sample (2 μl) heated was added to an ATP amplification reaction solution (50 μl), and an ATP amplification was performed for 60 minutes. The results are shown in Table 4. In Table 4, "tap water (1)" was obtained from a water supply in Hiroshima city. "Tap water (2)" is a water recycled in the Hiroshima University. "Bottled water" was purchased commercially. "Sterilized water" was prepared by autoclaving distilled water. "Pond water" is the water of a pond at the Hiroshima University. The number of colonies (CFU) was obtained by applying 1 ml of a water sample on a nutrient agar medium (1.6 g of tryptone, 1 g of yeast extract, 0.5 g of NaCl, 15 g of agar, and 1 L of water) and counting the colonies formed after 3 days of cultivation at 28°C.

Table 4

Sample source	Luminescence (rlu)		Number of colonies (CFU)
	ATP amplification		
	Without	With	
Tap water (1)	15	1,400	33
Tap water (2)	13	413	1
Bottled water	30	239	>1
Sterilized water	23	254	>1
Pond water	9	3100	59

[0067] The results indicate that bacteria could be detected even at a level at which they cannot be detected by the conventional bioluminescence assays. As shown by the results in Table 4, it is found that it is possible to detect 1 CFU/ml of bacteria by subjecting the water samples to an ATP amplification treatment for 60 minutes by using the method of the present invention. The conventional method using a nutrient medium typically requires several days to detect bacterial contamination (Table 4). It has been reported that Pseudomonas aeruginosa, which is a pathogenic bacterium, was detected in tap water (Bert, F. et al., "Multi-resistant Pseudomonas aeruginosa outbreak associated with contaminated tap water in a neurosurgery intensive care unit," J. Hosp. Infect., vol. 39, pp. 53-62 (1998)), and the presence of such a microorganism can be detected easily and rapidly according to the present invention.

(Example 7: Detection of bacteria in milk)

[0068] The application in dairying was examined. Since bacterial contamination causes extensive damage in the milk industry, rapid and reliable tests for detecting bacteria in milk have been developed. The inventor of the present invention

EP 1 652 934 A1

further examined a high-sensitive assay for detecting *Staphylococcus aureus* in milk. A growth culture of *Staphylococcus aureus* was diluted to an appropriate concentration and added to milk. In order to remove non-bacterial ATP derived from mammary gland and somatic cells that is contained in milk, 0.5 ml of milk were filtrated through a 0.45 μ m membrane filter. This membrane filter was washed with 10 ml of a solution containing 0.2% Triton X-100, 100 mM Tris-HCl (pH 7.8), and 2 mM EDTA (Olsoon, T. et al., "Extraction and determination of adenosine 5'-triphosphate in bovine milk by the firefly luciferase assay. Biotech," Appl. Biochem, vol. 8, pp. 361-369 (1986)). After washing, this membrane filter was dipped into 200 μ l of a lysis buffer, and heated to 100°C for 5 minutes. The heated sample (20 μ l) was subjected to an ATP amplification for 60 minutes. Then, the sample was used for a bioluminescence assay. The results are shown in Table 5.

Table 5

Number of <i>S. aureus</i> , cells (CFU) /0.5 ml milk	Luminescence (rlu)	
	ATP amplification	
	Without	With
750,000	399	39,491
75,000	84	10,011
7,500	47	4,141
750	50	1,790
75	37	1,156
0	49	432

[0069] As a result of the assay, 75 CFU (*Staphylococcus aureus*)/0.5 ml milk could be detected. Although the sensitivity in the detection of *Staphylococcus aureus* was lower than that of *E. coli*, the sensitivity in the detection of *Staphylococcus aureus* in milk was enhanced to about 10,000 times higher than that of a conventional bioluminescence assay. The method for rapidly determining the presence of a microorganism of the present invention is applicable to not only microorganisms in the environment but also a wide range of hygiene monitoring techniques.

Industrial Applicability

[0070] The PPK-ADK fusion protein of the present invention acts on a mixture of ATP, AMP, and a polyphosphate compound to amplify ATP. In particular, by using a PPK-ADK that does not contain ADP, which is an impurity, it becomes possible to amplify exogenous ATP, so that ATP derived from a microorganism at a single cell level can be amplified. The amplified ATP can be detected by a luciferase assay, for example. Therefore, a microorganism, detection of which has conventionally taken at least several days, can be detected very rapidly, and furthermore, even only a single cell can be detected.

EP 1 652 934 A1

SEQUENCE LISTING

5 <110> Japan Science and Technology Agency
 <120> Improved method for amplification of ATP and use thereof
 <130> P28551EP-PCT/MRM
 10 <160> 4
 <170> PatentIn version 3.1
 <210> 1
 <211> 30
 15 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> ppk forward primer
 20 <400> 1
 ggatctagat gaataaaacg gagtaaaagt 30
 <210> 2
 <211> 42
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> ppk reverse primer
 30 <400> 2
 ggaggatccg ccgcccgc cttcaggttg ttcgagtgat tt 42
 <210> 3
 <211> 30
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> adk forward primer
 40 <400> 3
 ggaggatcca tgcgtatcat tctgcttggc 30
 <210> 4
 <211> 27
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> adk reverse primer
 50 <400> 4
 gaaagcttg ccgaggattt tttccag 27
 55

Claims

5 1. A method for amplifying ATP comprising: allowing a fusion protein of a polyphosphate kinase and an adenylate kinase to act on a mixture containing ATP, AMP, and a polyphosphate compound.

2. The method of claim 1, wherein the fusion protein of a polyphosphate kinase and an adenylate kinase is a fusion protein that does not contain ADP.

10 3. A method for detecting ATP comprising:

allowing a fusion protein of a polyphosphate kinase and an adenylate kinase to act on a mixture of ATP, AMP, and a polyphosphate compound to amplify ATP; and detecting the amplified ATP.

15 4. The detection method of claim 3, wherein the fusion protein of a polyphosphate kinase and an adenylate kinase is a fusion protein that does not contain ADP.

5. A method for rapidly detecting the presence of a microorganism comprising:

20 treating a sample containing a microorganism to prepare a sample containing ATP;
adding the sample containing ATP to an ATP amplification system to amplify ATP; and
detecting the amplified ATP,
wherein the ATP amplification system comprises AMP, a polyphosphate compound, and a fusion protein of a
polyphosphate kinase and an adenylate kinase, the fusion protein not containing ADP.

25 6. A kit for rapidly detecting the presence of a microorganism, comprising an ATP amplification reagent containing AMP, a polyphosphate compound, and a fusion protein of a polyphosphate kinase and an adenylate kinase, the fusion protein not containing ADP; and an ATP detection reagent for detecting ATP.

30 7. The kit of claim 6, further comprising a cell lysis reagent.

8. A method for amplifying ATP by allowing an adenylate kinase and a polyphosphate kinase that does not contain ADP to act on a mixture of ATP, AMP, and a polyphosphate compound.

35 9. A fusion protein of a polyphosphate kinase and an adenylate kinase.


10. A fusion protein of a polyphosphate kinase and an adenylate kinase, which does not contain ADP.

Fig. 1

(a) In the absence of ATP



(b) In the presence of ATP



ADK: adenylate kinase
PPK: polyphosphate kinase

Fig. 2




Fig. 3





Fig. 4



INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/011186

A. CLASSIFICATION OF SUBJECT MATTER Int.Cl ⁷ C12Q1/48, 1/04, C12N9/12, G01N33/50, C07K19/00//C12N15/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) Int.Cl ⁷ C12Q1/48, 1/04, C12N9/12, C07K19/00		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) BIOSIS (DIALOG), WPI (DIALOG), JSTPlus (JOIS), PubMed		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JP 2001-299390 A (Satake Corp. et al.), 30 October, 2001 (30.10.01), & WO 01/53513 A1 & EP 1264894 A1 & US 2003/0064394 A1	1-10
Y	Kohei SHIMOMURA et al., "Rensateki ATP Zofuku Hanno ni yoru Biryo ATP no Kenshutsu Gijutsu Kaihatsu", The Society of Chemical Engineers, Japan Nenkai Kenkyu Happyo Koen Yoshishu, 2001, Vol.66th, page 647	1-10
<u>Y</u> <u>A</u>	Brune M. et al., Cloning and sequencing of the adenylate kinase gene (adk) of Escherichia coli., Nucleic Acids Res., 1985, Vol.13, No.19, pages 7139 to 7151	<u>1-7, 9, 10</u> 8
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents:		
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	
"P" document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search 24 August, 2004 (24.08.04)	Date of mailing of the international search report 07 September, 2004 (07.09.04)	
Name and mailing address of the ISA/ Japanese Patent Office	Authorized officer	
Facsimile No.	Telephone No.	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/011186

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
<u>Y</u> <u>A</u>	AKIYAMA, M. et al., The Polyphosphate Kinase Gene of Escherichia coli., J.Biol.Chem., 1992, Vol.267, No.31, pages 22556 to 22561	<u>1-7, 9, 10</u> 8
<u>Y</u> <u>A</u>	JP 2002-530087 A (Neose Technologies, Inc.), 17 September, 2002 (17.09.02), & WO 00/29603 A2 & EP 1131415 A2 & US 2002/0001831 A1	<u>1-7, 9, 10</u> 8
<u>Y</u> <u>A</u>	JP 2002-543798 A (Medical Research Council), 24 December, 2002 (24.12.02), & WO 00/68418 A1 & EP 1177314 A1	<u>2, 4-8, 10</u> 1, 3, 9

Form PCT/ISA/210 (continuation of second sheet) (January 2004)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/011186

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

(See extra sheet.)

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/011186

Continuation of Box No.III of continuation of first sheet(2)

((Reference))

1. JP 2001-299390 A (Satake Corp. et al.)
30 October, 2001 (30.10.01)

The invention claimed in claims 1-7, 9 and 10 relates to a fused protein of adenylate kinase and polyphosphoric acid kinase.

On the other hand, the invention claimed in claim 8 relates to a method of amplifying ATP, comprising causing adenylate kinase and polyphosphoric acid kinase to act on a mixture of ATP, AMP and polyphosphoric acid compound.

Consequently, the invention claimed in claims 1-7, 9 and 10 and the invention claimed in claim 8 are common to each other in relating to adenylate kinase and polyphosphoric acid kinase.

However, as the Reference 1 describes the amplification of ATP effected by the use of adenylate kinase and polyphosphoric acid kinase, it does not appear that the invention claimed in claims 1-7, 9 and 10 and the invention claimed in claim 8 share technical features contributory over the prior art and that the inventions are linked with each other so as to form a single general inventive concept.

Therefore, it appears that this application involves a total of two inventions consisting of the invention claimed in claims 1-7, 9 and 10 and the invention claimed in claim 8.